Dr. Philip A. Van Damme Director for CanChew Biotechnologies a subsidiary of Medical Marijuana Inc. (Pink Sheets: MJNA), called into SmallCapVoice.com to go over the science, history and applications for the patented technology which comprises the inclusion of regulatory acceptable active pharmaceutical ingredients [API] of the cannabinoid variety in a patented and proprietary chewing gum delivery formulation. CanChew® for medical purposes, specifically pain treatment associated with a variety of long term, chronic or degenerative diseases whereby cannabinoid therapy is finding increasing application in a global marketplace.